| Expression pattern: |
UP |
| Associated gene: |
BCL-2 |
| Associated microRNA: |
- |
| Biological function: |
circFARSA is highly expressed in pancreatic cancer and functions as an anti-cancer therapeutic target; inhibition of circFARSA suppresses pancreatic cancer cell proliferation and migration, induces apoptosis, arrests the cell cycle in G0/G1 phase, and inhibits tumor growth in patient-derived xenograft mice. |
| Molecular mechanism: |
siRNA-circFARSA inhibits circFARSA expression, decreases BCL-2 protein expression, inhibits BCL-2-related anti-apoptotic signaling, and promotes pancreatic cancer cell apoptosis. |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); apoptosis (inhibits); cell cycle (promotes); other pathway/process (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Transfection; CCK8; Transwell Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Western Blot; In Vivo Animal Model; H&E Staining |
| Clinical significance: |
circFARSA is proposed as a novel target for pancreatic cancer treatment; pSiNP-PEI-siRNA-circFARSA is proposed as a promising anti-pancreatic cancer agent with high biosafety and anti-cancer effects. |
| Description: |
circFARSA is up-regulated in pancreatic cancer cell lines and patient-derived pancreatic cancer tumor tissue, supporting its role as a therapeutic target. Silencing circFARSA with siRNA-circFARSA suppresses proliferation, migration, cell-cycle progression and tumor growth, while promoting apoptosis through reduced BCL-2 protein expression and inhibition of BCL-2-related anti-apoptotic signaling. The study develops pSiNP-PEI-siRNA-circFARSA as a safer and more effective delivery system for pancreatic cancer treatment. |
| Confidence score: |
0.5445 |